Loratadine OTC Switch Profitable For Payers And Consumers, Study Finds
This article was originally published in The Pink Sheet Daily
Executive Summary
The Rx-to OTC switch of Claritin (loratadine) decreased cost to payers, whether changes to formulary status for antihistamines were made or not, according to a study in the American Journal of Managed Care. Mean copay costs were higher than OTC price, Sullivan et al. maintain.